| Code | CSB-RA017647MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to MIL86, targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a secreted serine protease that plays a critical role in cholesterol homeostasis by binding to low-density lipoprotein receptors (LDLR) on hepatocyte surfaces, promoting their lysosomal degradation. By reducing LDLR availability, elevated PCSK9 levels lead to increased circulating LDL cholesterol, a major risk factor for atherosclerotic cardiovascular disease. Loss-of-function mutations in PCSK9 are associated with reduced LDL cholesterol and lower cardiovascular risk, while gain-of-function mutations cause familial hypercholesterolemia.
MIL86 is a well-characterized reference antibody that inhibits PCSK9 function by preventing its interaction with LDLR, thereby increasing receptor availability and enhancing LDL cholesterol clearance. This biosimilar antibody serves as a valuable research tool for investigating PCSK9 biology, lipid metabolism pathways, and cardiovascular disease mechanisms. It enables studies exploring cholesterol regulation, receptor trafficking, and potential therapeutic interventions for dyslipidemia and related metabolic disorders.
There are currently no reviews for this product.